Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PMA DRUG ABUSE COMMISSION LED BY EX-FDAers MEYER AND NOVITCH has been established to coordinate the efforts of the Alcohol, Drug Abuse and Mental Health Administration (ADAMHA), the National Institute on Drug Abuse (NIDA) and U.S. pharmaceutical manufacturers to "speed the development and use of medicines to fight drug dependency." The Pharmaceutical Manufacturers Association announced the establishment of the PMA Commission on Medicines for the Treatment of Drug Dependency and Abuse at a Nov. 27 press conference in Washington, D.C. Heading up the commission are two former FDAers. Chairing the group is American Cyanamid Medical Research Division President Harry Meyer, MD, formerly a director of the Center for Drugs and Biologics. The commission's vice chairman is Upjohn Exec VP Mark Novitch, MD, a former FDA deputy commissioner. PMA Senior VP/Science and Technology John Beary, MD, is the new commission's executive director. The drug abuse commission will liaise with NIDA on four areas: consulting on the development of screening programs for new drug abuse treatment candidates; developing guidelines on which compounds to submit for screening; communicating NIDA "goals, programs and progress to PMA companies"; and seeking support for research into treatments for drug dependency and abuse. Meyer and Novitch will be joined by seven commissioners, all researchers at PMA-member companies. They are: Wellcome Research Labs VP-R&D and Medical Affairs David Barry, MD; DuPont senior research fellow-CNS diseases Leonard Cook PhD; Lilly fellow-clinical research Louis Lemberger, MD; Wyeth-Ayerst research scientist Karen Marquis , PhD; Merck Executive Director of Clinical Neuroscience Scott Reines, MD/PhD; Syntex Exec VP and Director of Medical Research and Pharmaceutical Development Robert Roe, MD; and Roche Institute of Molecular Biology's head of neurosciences Sydney Spector, PhD.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts